Division of Teva Pharmaceutical Industries Ltd.
Latest From Pliva DD
More than 50 metamizole-containing medicines are being reviewed by the European Medicines Agency because of substantial differences in their national product labeling regarding dosage and contraindications in pregnant and breastfeeding women.
Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.
Highlights from the Q3 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was more than twice that of Q2 with 105 deals bringing in over $4.4 billion, but not one IPO to be found. M&A dollars also nearly doubled to $23 billion in the third quarter--versus the previous three months--and of the 26 transactions with known values, more than half were over $100 million. Alliances saw activity focused primarily in two areas: drug delivery and large molecules, each category with 16 deals apiece. Total potential deal value (for the 43 alliances with known values) reached $4.5 billion, over one and a half times that of the previous quarter.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
- Topical Delivery
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Eastern Europe
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Ivan Mijatovic, CFO
Zeljko Covic, Pres. & COO
Dubravko Mak, VP, Global Bus. Dev.
- Contact Info
Phone: (385) 1 61 20 999
Ulica grada Vukovara 49